

developing tumors (178, 179), and older patients with more accumulated mutations prior to cell expansion will also be at increased risk.

Expansion of T cells *ex vivo* presents additional risks. As most of the mechanisms that eliminate mutant cells *in vivo*, particularly those that are immune mediated, do not apply to cells in culture, there is an increased likelihood of retaining cells with new mutations. In addition, mutations that occur in any of the many genes that regulate DNA repair will compromise the repair processes and enhance the mutation rate. Furthermore, expanding T cells *ex vivo* entails removing them from their natural environment with percent oxygen levels between 5% and 10% to culture conditions where ambient oxygen is about 20%. As culture of cells at ambient oxygen versus culture at 3% oxygen significantly increases mutation rates (180, 181), *ex vivo* expansion of T cells under standard culture conditions for autologous transplant should be considered an additional risk factor. Clearly, *in vivo* and *ex vivo* T-cell expansion confers some risk for secondary T-cell malignancies. The risk is likely quite low but will vary according to individual genetic makeup (e.g., DNA repair capacity), patient age, magnitude and nature of genetic modifications, nature of vectors used (e.g., self-inactivating lentivirus versus conventional, retrovirus vectors), as well as the scale and methods employed for the *in vitro* culture and expansion of the transduced cells.

Adverse effects of immunotherapies and their management

Most, but not all, immunotherapy-related adverse effects are of the short-term type such as cytokine storm. However, there are concerns of longer-term effects such as the potential for increased risk of autoimmune disease following treatment with PD-1 or CTLA-4 inhibitors (23, 182). In addition, there are possible risks for acquiring somatic mutations during *ex vivo* and induced *in vivo* T-cell expansion that is necessary for autologous or allogeneic adoptive T-cell strategies. Possible mutational risks associated with large-scale expansion of universal CAR T cells for "off-the-shelf" CAR T-cell therapy must also be considered. For autologous CAR T-cell therapy, a patient's T cells are first recovered from peripheral blood, transduced with a retrovirus or lentivirus harboring a CAR against a tumor-specific antigenic determinant, expanded several fold, and infused into the patient. The concern arises when one considers the rate of mutation in somatic cells. Determining the mutation rate in mammalian cells *in vivo* is also relevant when considering the extent of T-cell expansion after activation.

CAR T cells and therapies

The intricacies of the immune signaling systems and their multiple regulatory feedback circuits are critical for maintaining a homeostatic balance in immune-mediated rejection and tolerance, which when perturbed can have serious consequences. The PD-1/PD-L1 inhibitory interaction, for example, serves not only the unwanted function of protecting the tumor, but is part of the mechanism that allows the body to discriminate between "self" as "non-self". As PD-1 is expressed in many tissues and cell types, alleviation of the PD-1/PD-L1 inhibitory mechanism runs the risk of inducing systemic adverse effects of varying degrees including autoimmune disease or "immune-related adverse events" (183). Similar concerns exist for suppressing immune inhibition mediated by CTLA-4 (184, 185).

Like overcoming the immune checkpoint for therapeutic purposes, the use of CAR T cells is not without its challenges and risks.

Probably the most common adverse effect after CAR T-cell infusion is immune-mediated cytokine release syndrome (CRS) or "cytokine storm" which manifests as high fever, myalgia, anorexia, tachycardia, hypotension among other symptoms, and can sometimes be fatal (186–188). Although concerning, CRS can be fully reversed by corticosteroids, such as prednisone (95), which, however, runs the risk of compromising the therapeutic effect of the CAR T cells. An alternative approach based on the remarkable elevation of IL6 that has had considerable clinical success for managing and alleviating CRS symptoms is the administration of tocilizumab, a mAb directed to the IL6 receptor (189). Another challenge with CAR T-cell strategies is on-target (correct antigen target) off-target/off tumor (incorrect cell type target) concerns. Renal cell carcinomas (RCC), for example, express high levels of carboxy-anhydrase-IX (CAIX) at their cell surface (190). When patients with metastatic RCC were treated with CAIX CAR T cells, several developed liver toxicity due to CAR T-cell interaction with bile duct epithelial cells expressing CAIX (191). Similarly, a patient with a recurrent and metastatic ERBB2-expressing tumor, when treated with ERBB2 CAR T cells, displayed pulmonary toxicity due to ERBB2 expression in the lungs (192). Likewise, when patients with melanoma or myeloma expressing the MAGE-A3 antigen were infused with MAGE-A3 CAR T cells, they developed severe cardiotoxicity due to cross reactivity to a titin determinant that was expressed on cardiomyocytes (193).

Most attention in clinical CAR T-cell experience has been with B-cell malignancies where CD 19 has been the redirected T-cell target. The approach has been relatively successful in eradicating the malignancy with the caveat that the strategy also eliminates most of the normal cells of B-cell lineage as they also express the CD19 marker (94). The loss of normal B cells and consequent off-tumor target toxicity, however, can be managed by immunoglobulin transfer to compensate for lost B cells (94). A modification of the single chimeric antigen receptor that enhances specificity is the development of a dual CAR T-cell strategy. This modification, which involves inclusion of a second chimeric antigen receptor targeting CD123 (IL3 receptor α chain), has been instrumental in overcoming evasion of CD19 CAR T-cell cytotoxicity or relapse by eliminating B-ALL cells that are CD19 negative (194). Evasion of CD19 CAR T cells by B-cell malignancies can arise due to a subset of cells that express an alternatively spliced CD19 variant that is not recognized by the CAR in the armed T cell. Inclusion of the CD123 chimeric antigen receptor eliminates the residual CD19-negative malignant B cells that also express the CD123 marker as well as those cells that have lost the CD 19 marker by acquired mutation and that contribute to CD19 CAR T-cell-resistant relapse (195). The CD123 marker is expressed on cells of the myeloid lineage and is a target for CD123 CAR T-cell therapy (196). One caveat with targeting CD123 for AML, for example, is that this marker is found on most myeloid cells and also on hematopoietic stem cells (197). Clinically, however, this may not be a serious problem (194), although this contention remains under debate (198, 199). In addition, in hematologic malignancies, where hematologic stem cell transplants (HSCT) are routinely employed to consolidate the often transitory remission following chemotherapy, CAR T-cell therapy could provide a so-called "bridge-to-transplant" allowing hematopoietic reconstitution by subsequent chemotherapy-mediated elimination of the CAR T cells and HSC transplantation.

The use of CAR T-cell approaches for solid tumors have been less successful than those for B-cell malignancies. This is in part

because useful surface markers that are unique to the tumor are not common. To overcome the issue of specificity, CAR T cells with dual specificity have been designed with the idea that requiring both antigens to be engaged would increase specificity of the CAR T cells to the intended target (199–201). In a mouse glioblastoma xenograft model, optimal epitopes for HER2 and IL13 receptor $\alpha 2$ were designed by *in silico* modeling, and CAR T cells with chimeric antigen receptors targeting both epitopes were generated. The dual specificity CAR T cells appeared to have greater antitumor efficacy than CAR T cells expressing either CAR alone, and the animals survived for a longer time (202). While this dual specificity CAR T cell was efficacious in a murine xenograft model, its utility in an immunocompetent environment is unclear.

A very elegant CART-cell model that overcomes this reservation utilizes a synthetic modular Notch receptor (203) designed to recognize one ligand on a tumor cell and a third-generation CAR that recognizes a second antigen on the same tumor cell (204). The extracellular domain of the synthetic Notch receptor, whose normal ligand is Delta, was replaced with an extra cellular domain that recognizes a tumor antigen (antigen A). The intracellular Notch domain that is cleaved after ligand binding to the extracellular domain was replaced with a fragment that acts as a transcription factor that induces CAR expression to engage a second tumor antigen (antigen B) to initiate tumor cell cytolysis. To be killed selectively by the CAR T cell, therefore, the tumor must express both antigens. Any nontumor cell that expresses only one of the antigens will be spared. Of course, given tumor heterogeneity, it would not be surprising if some tumors contained a subpopulation of cells expressing only one or the other of the antigens, thereby escaping cytolysis by this approach and providing the seed for local tumor recurrence or metastasis. This concern has been addressed by the use of a bispecific CAR that enabled complete cytolysis of malignant B cells with no evidence of escape (205). These CAR T cells harbor reengineered single-chain bispecific antibodies that target both CD19 and CD20. Thus, malignant B cells that have lost CD 19, which normally would render them resistant to CAR T19 cell therapy, retain CD20 and are killed. It is also of course possible, though not yet directly demonstrated, that CAR-mediated lysis of a substantial population of tumor cells may in turn stimulate further immunologic responses against other tumor-associated antigens. This would produce an "antigen spread" and promote elimination of tumor cells that lack the CAR-targeted antigen(s). A related strategy involves direct administration of single molecule bispecific antibodies that target tumor cells (e.g., CD19) and T cells [e.g., a CD3 subunit TCR] to promote the engagement of the two cell types, activation of the coupled T cells and cytolysis of the target cells (206). This type of bispecific antibody, designated bispecific T-cell engager (BiTE), is currently under assessment by several clinical trials (206, 207).

Overcoming a hostile tumor environment

Overcoming a hostile immunosuppressive tumor microenvironment represents a major hurdle for CAR T-cell therapy. The tumor microenvironment is a highly complex network of tumor cells, stromal cells, activating and inhibitory cells of the immune system, vasculature, cytokines, and intercellular milieu that is generally immunosuppressive and an environment that favors tumor growth. As previously discussed, elevated local adenosine levels are inhibitory to CTLs and their ability to infiltrate the tumor. Reducing the local adenosine concentration by inhibiting

ectonucleotidases (126–128) or suppressing adenosine uptake by blocking the adenosine receptor (122–124) represent alternative approaches to restoring CD8⁺ T-cell, or CART-cell infiltration and activity. An additional approach for modifying the local tumor environment utilizes CAR T cells armed with the ability to secrete a cytokine (208). A major focus of this approach has centered on IL12 which exerts its antitumor activity by acting on NK cells and CD8⁺ cells, and inducing the local production of IFN γ (209). CAR T cells that were modified to secrete IL12 have enhanced antitumor activity in a preclinical murine model (210, 211). However, a clinical trial in which melanoma patients were treated with TILs genetically modified to secrete IL12, encountered significant toxicities (212). Another recent report describes a phase I clinical trial in which MUC16 CART cells were further modified to secrete IL12 for treatment of patients with advanced, recurrent ovarian cancer (213), but no adverse effects have been reported to date. Tumor-associated stromal cells also contribute to the immunosuppressive microenvironment, mediated in part by elevated expression of fibroblast activation protein- α (FAP; ref. 214). When FAP expressed in stromal cells was targeted with CAR T cells in a preclinical cancer model, tumor cell growth was inhibited (215). Similarly, when stromal cells that express FAP in a murine model were eliminated, tumor-infiltrating CD8⁺T cell activity and longer survival of mice harboring tumors were enhanced (216). Thus, adapting the tumor microenvironment to favor tumor eradication is fraught with obstacles but presents an encouraging approach.

Patient safety is paramount as evidenced by the recent temporary halting of a phase II clinical trial by the FDA. Patients with refractory ALL had received fludarabine plus cyclophosphamide prior to CD19 CAR T-cell infusion. Three patients less than 25 years of age developed cerebral edema and died while treated under this protocol and the FDA halted the trial. The fludarabine had been added to the preconditioning protocol and appeared to be the cause of the deaths. Shortly thereafter, the FDA allowed the trial to continue, but only after fludarabine was removed from the preconditioning protocol.

Patient safety and alleviation of therapeutic cost

While patient safety remains a constant concern, probably the biggest obstacle for autologous CAR T-cell therapy is the cost, which has been estimated to be as high as \$400,000 to \$500,000. Even if this price is exaggerated, the high cost should not be surprising given the degree of personalized clinical care required for current autologous CART-cell therapy protocols. As a first step, patient-derived T cells are recovered, often by leukapheresis, and the recovered T cells are stimulated to proliferate to facilitate their genetic modification by infection with a γ -retrovirus or lentivirus encoding the CAR construct. The *ex vivo*-transduced T cells are then expanded about 10-fold at which point the cell preparation is ready for patient infusion. This multistep process must be repeated for each patient, accounting in part for the very high cost.

To alleviate the high price of individualized CART-cell therapy, "universal" engineered T cells have been generated. These have the advantage that they can be expanded into large batches and used as "off the shelf" therapeutic allogeneic CAR T cells with broad applicability (216). The TCR has been disrupted by TALEN-mediated site-specific mutagenesis to eliminate the risk of graft versus host disease. Similarly, CD52, which is broadly expressed on multiple hematologic cell lineages, is also eliminated, thus rendering these cells resistant to the anti-CD52 mAb

alemtuzumab, which is frequently employed in the treatment of hematologic malignancies. Therefore, these cells can be used in the context of alemtuzumab conditioning of the patient, which reduces the leukemic burden while concomitantly conferring a selective advantage to the allogeneic CAR T cells, including the reduced risk of rejection of these HLA-mismatched cells by the host (217). In brief, donor T cells are collected by leukapheresis, activated in culture, TCR is inactivated by site-directed mutagenesis, and transduced with a lentivirus vector harboring the CAR of interest. The cells are expanded about 10 fold to yield about 10^{10} genetically engineered "universal" T cells. From each batch prepared, aliquots are frozen, and thawed for use as needed. Treatment of an 11-month girl with relapsed CD19⁺ B-ALL provided an opportunity for clinically relevant proof of principle. The patient received a single dose of the "universal" CAR T cells, designated UCART19 cells, and has undergone complete molecular and clinical remission, within the limits of detection (218).

The advances in our understanding of the biology of how our bodies distinguish "self" from "non-self" during the last 60 years have been remarkable, and the degree to which this understanding is being applied to anticancer therapies is encouraging. As Helen Keller once remarked, "Optimism is the faith that leads to achievement. Nothing can be done without hope and confidence" (219). Given the many distant and recent accomplishments, optimism is clearly applicable to the future of cancer immunotherapy. As described above, the hurdles that remain for achieving a uniformly curative anticancer immunotherapy strategy are significant but it is likely that all can be overcome or circumvented. Particularly encouraging is the idea that immunotherapy approaches can be complemented by or combined with surgery or with other developing strategies. These include targeting of biochemical pathways that are key to tumor survival or manipulating the tumor microenvironment rendering it hostile to tumor viability. Decisions by oncologists regarding optimal treatment

strategies in the future will require a personalized or "precision" approach taking into account variations in genomic, transcriptomic, proteomic, and metabolomic profiles for a given tumor and patient. While currently in its infancy, the promise of such a comprehensive approach is enormous, and the expectation that cancer will be managed as a chronic disease, if not commonly cured, is becoming reality.

Disclosure of Potential Conflicts of Interest

J. Maher is a chief scientific officer at Leucid Bio. F. Farzaneh reports receiving a commercial research grant from Autolus, Collectis, speakers bureau honoraria from Autolus and Collectis, has ownership interest (including patents) in Autolus, and is a consultant/advisory board member for Autolus. No potential conflicts of interest were disclosed by the other authors.

Disclaimer

The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

Acknowledgments

The authors thank Glenn Doerman for preparation of the figures and Michael Lieberman, Susanne Wells, and Laura Conforti for critical reading of the manuscript.

Grant Support

This work was supported in part by the University of Cincinnati as a sabbatical leave for P.J. Stambrook. Related research is supported by the Experimental Cancer Medicine Centre at King's College London and by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Guy's and St Thomas' NHS Foundation Trust and the BRC based at the Institute of Psychiatry in partnership with King's College Hospital NHS Trust and King's College London. This work is also supported by the Experimental Cancer Medicine Centre at King's College London.

Received November 28, 2016; revised December 22, 2016; accepted January 14, 2017; published OnlineFirst March 29, 2017.

References

- Park HW. Germs, hosts, and the origin of Frank Macfarlane Burnet's concept of "self" and "tolerance," 1936-1949. *J Hist Med Allied Sci* 2006; 61:492-534.
- Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. *Nature* 1953;172:603-6.
- Mitchison NA. Passive transfer of transplantation immunity. *Nature* 1953;171:267-8.
- Miller JFAP, Mitchell GF. Cell to cell interaction in the immune response I. Hemolysin-forming cells in neonatally thymectomized mice reconstituted with thymus or thoracic duct lymphocytes. *J Exp Med* 1968;128:801-20.
- Miller JFAP, Mitchell GF. Cell to cell interaction in the immune response II. The source of hemolysin-forming cells in irradiated mice given bone marrow and thymus or thoracic duct lymphocytes. *J Exp Med* 1968; 128:821-37.
- Jerne NK, Nordin AA. Plaque formation in agar by single antibody-producing cells. *Science* 1963;140:405.
- Miller JFAP. Events that led to the discovery of T-cell development and function—a personal recollection. *Tissue Antigens* 2004;63:509-17.
- Zinkernagel RM, Doherty PC. Restriction of *in vitro* T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. *Nature* 1974;248:701-2.
- Zinkernagel RM, Doherty PC. Immunological surveillance against altered self-components by sensitized T lymphocytes in lymphocytic choriomeningitis. *Nature* 1974;251:547-8.
- Schwartz RH. T-Lymphocyte recognition of antigen in association with gene products of the major histocompatibility complex. *Annu Rev Immunol* 1985;3:237-61.
- Sharpe AH, Freeman GJ. The B7-CD28 superfamily. *Nat Rev Immunol* 2002;2:116-26.
- Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. *Nat Rev Immunol* 2012;12:180-90.
- Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. *N Engl J Med* 1985;313:1485-93.
- Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. *Clin Cancer Res* 2008;14:5610-18.
- Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. *Cancer* 2008;113:293-301.
- Rosenberg SA. IL-2: The first effective immunotherapy for human cancer. *J Immunol* 2014;192:5451-58.
- Chen L, Ashe S, Brady WA, Hellstrom I, Ledbetter JA, McGowan P, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. *Cell* 1992;71:1093-1102.
- Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8⁺ T cells by B7-transfected melanoma cells. *Science* 1993;259: 368-70.
- Tirapu I, Huarte E, Guiducci C, Arina A, Zaratiegui M, Murillo O, et al. Low surface expression of B7-1 (CD80) is an immunoevasion mechanism of colon carcinoma. *Cancer Res* 2006;66:2442-50.

20. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. *Clin Cancer Res* 2012;18:2039–2047.
21. Chapuis AG, Lee SM, Thompson JA, Roberts IM, Margolin KA, Bhatia S. Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. *J Exp Med* 2016;213:1133–1139.
22. Ishida Y, Agata Y, Shibahara, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. *EMBO J* 1992;11:3887–3895.
23. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. *Immunity* 1999;11:141–151.
24. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J Exp Med* 2000;192:1027–1034.
25. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. *Nat Immunol* 2001;2:261–268.
26. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, et al. Naturally occurring human IgM antibody that binds B7-DC and potentiates T cell stimulation by dendritic cells. *J Exp Med* 2001;193:873–846.
27. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. *Curr Opin Immunol* 2011;24:207–212.
28. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. *Nat Med* 2002;8:793–800.
29. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. *Cancer* 2010;116:1757–1766.
30. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. *Clin Cancer Res* 2013;19:5300–5309.
31. Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trials. *Pigment Cell and Melanoma Res* 2015;28:245–253.
32. Powles T, Eder JP, Fine GD, Braiteh FS, Loria Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. *Nature* 2014;515:558–562.
33. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. *Clin Cancer Res* 2004;10:5094–5100.
34. Ameratunga M, Asadi K, Lin X, Walkiewicz M, Murone C, Knight S, et al. PD-L1 and tumor infiltrating lymphocytes as prognostic markers in resected NSCLC. *PLoS One* 2016;11:e153954.
35. Seiwert TY, Burtress B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. *Lancet Oncol* 2016;17:956–65.
36. Straub M, Drecoll E, Pfarr N, Weichert W, Langer R, Hapfelmeier A, et al. CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. *Oncotarget* 2016;7:12024–12034.
37. Lussier DM, O'Neill L, Nieves LM, McAfee MS, Holeczek SA, Collins AW, et al. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. *J Immunother* 2015;38:96–106.
38. Gaken JA, Hollingsworth SJ, Hirst WJ, Buggins AG, Galea-Lauri J, Peakman M., et al. Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors. *Hum Gene Ther* 1997;8:477–488.
39. Barnard AL, Farzaneh F, Gaken J, Darling D. Local versus systemic interleukin-2: tumor formation by wild-type and B7-1-positive murine melanoma cells. *Cancer Gene Ther* 2000;7:207–214.
40. Rosenberg SA. IL-2: The first effective immunotherapy for human cancer. *J Immunol* 2014;192:5451–5458.
41. Morgan DA, Ruscetti FW, Gallo R. Selective *in vitro* growth of T lymphocytes from normal human bone marrows. *Science* 1978;193:1007–1008.
42. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. *Nat Rev Cancer* 2008;8:299–308.
43. Smith C, Økern G, Rehan S, Beagley L, Lee SK, Aarvak T, et al. *Ex vivo* expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS immune cell serum replacement. *Clin Transl Immunol* 2015;4:e31.
44. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. *Science* 1986;233:1318–1321.
45. Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. *J Immunol* 1987;138:989–995.
46. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. *N Engl J Med* 1988;319:1676–1680.
47. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. *Science* 2015;348:62–68.
48. Seliger B. The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor genes, and transcription factors. *J Immunotoxicol* 2014;11:308–310.
49. Seliger B, Harders C, Wollscheid U, Staeger MS, Reske-Kunz AB, Huber C. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes. *Exp Hematol* 1996;24:1275–1279.
50. Versteeg R, Noordermeer IA, Kruse-Wolters M, Ruiter DJ, Schrier PI. *c-Myc* down-regulates class I HLA expression in human melanomas. *EMBO J* 1988;7:1023–1029.
51. Peltenburg LT, Dee R, Schrier PIDownregulation of HLA class I expression by *c-myc* in human melanoma is independent of enhancer A. *Nucleic Acids Res* 1993;21:1170–1185.
52. Bernards R, Dessain SK, Weinberg RA. N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma. *Cell* 1986;47:667–674.
53. Lenardo M, Rustgi AK, Schievella AR, Bernards R. Suppression of MHC class I gene expression by N-myc through enhancer inactivation. *EMBO J* 1989;8:3351–3355.
54. van't Veer LJ, Beijersbergen RL, Bernards R. N-myc suppresses major histocompatibility complex class I gene expression through down-regulation of the p50 subunit of NF-kappa B. *EMBO J* 1993;12:195–200.
55. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KMYC regulates the antitumor immune response through CD47 and PD-L1. *Science* 2016;352:227–231.
56. Bradley SD, Chen Z, Melendez B, Talukder A, Khalili JS, Rodriguez-Cruz T, et al. BRAFV600E co-opts a conserved MHC class I internalization pathway to diminish antigen presentation and CD8+ T-cell recognition of melanoma. *Cancer Immunol Res* 2015;3:602–609.
57. Bradley SD, Melendez B, Talukder A, Lizée G. Trouble at the core: BRAF (V600E) drives multiple modes of T-cell suppression in melanoma. *Oncoimmunology* 2015;55:e1078966.
58. Inoue M, Mimura K, Izawa S, Shiraishi K, Inoue A, Shiba S, et al. Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression. *Oncoimmunology* 2012;1:1104–1110.
59. Choudhury A, Charo J, Parapuram SK, Hunt RC, Hunt DM, Seliger B, et al. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. *Int J Cancer* 2002;108:71–77.
60. Xu H, Aldrich MC, Chen Q, Liu H, Peterson NB, Dai Q, et al. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. *J Am Med Inform Assoc* 2015;22:178191.
61. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. *Brit Med J* 2005;330:1304–1305.
62. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer. *Diabetes Care* 2009;32:1620–1623.
63. Bodmer M, Meier C, Krahenhuhl S, Jick SS, Meier CR. Long-term metformin use was associated with decreased risk of breast cancer. *Diabetes Care* 2010;33:1304–1308.

64. Hatoum D, McGowan EM. Recent advances in the use of metformin: can treating diabetes prevent breast cancer? *Biomed Res Int* 2015;2015: 548436.
65. McFarland MS, Cripps R. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs. *Pharmacotherapy* 2010;30:1159–1178.
66. Oliveras-Ferreras C, Cufi S, Vazquez-Martin A, Menendez OJ, Bosch-Barrera J, Martin-Castillo B, et al. Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. *Cell Cycle* 2012;11:974–989.
67. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. *Proc Natl Acad Sci U S A* 2015;112:1809–1814.
68. Chan L, Hardwick N, Darling D, Galea-Lauri J, Gäken J, Devereux S, et al. IL-2/B7.1 (CD80) fusagenic transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell activation and cytolytic activity: generate whole cell vaccines for AML. *Mol Ther* 2005;11:120–131.
69. Ingram W, Chan L, Guven H, Darling D, Kordasti S, Hardwick N, et al. Human CD80/IL-2 lentivirus transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for immunotherapy. *Br J Haematol* 2009;145:749–780.
70. Kuhns MS, Davis MM, Garcia KC. Deconstructing the form and function of the TCR/CD3 complex. *Immunity* 2006;24:133–139.
71. Guy CS, Vignali DAA. Organization of proximal signal initiation at the TCR:CD3 complex. *Immunol Rev* 2009;232:7–21.
72. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. *Proc Natl Acad Sci U S A* 1989;86:10024–10028.
73. Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. *J Exp Med* 1995; 181:1653–1659.
74. Brocker T. Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells. *Blood* 2000;96:1999–2001.
75. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. *Nature Biotechnol* 2002;20:70–75.
76. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. *Leukemia* 2004;18: 676–684.
77. Diehn M, Alizadeh AA, Rando OJ, Liu CL, Stankunas K, Botstein D, et al. Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. *Proc Natl Acad Sci U S A* 2002;99:11796–11801.
78. Peters PJ, Borst J, Oorschot V, Fukuda M, Krähenbühl O, Tschopp J, et al. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. *J Exp Med* 1991;173:1099–1109.
79. Ju S-T, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH, et al. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. *Nature* 1995;373:444–448.
80. van der Stegen SJ, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. *Nat Rev Drug Discov* 2015;14: 499–509.
81. Whilding LM, Maher J. CART-cell immunotherapy: The path from the by-road to the freeway. *Mol Oncol* 2015;9:1994–2018.
82. Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. *Nat Rev Clin Oncol* 2016;13:273–290.
83. Gross G, Eshhar Z. Therapeutic potential of T cell chimeric antigen receptors in cancer treatment: counteracting off-tumor toxicities for safe CAR T cell therapy. *Annu Rev Pharmacol Toxicol* 2016;56:59–83.
84. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. *Blood* 2014;123:2625–2635.
85. Firor AE, Jares A, Ma Y. From humble beginnings to success in the clinic: chimeric antigen receptor-modified T-cells and implications for immunotherapy. *Exp Biol Med* 2015;240:1087–1098.
86. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. *Sci Transl Med* 2011; 3:95ra73.
87. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. *Blood* 2010;116:4099–4102.
88. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. *Blood* 2012;119:2709–2720.
89. Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. *Blood* 2013;122:4129–4139.
90. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. *J Clin Oncol* 2015;33:540–549.
91. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *N Engl J Med* 2011;365:725–733.
92. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. *Sci Transl Med* 2015;7:303ra139.
93. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *N Engl J Med* 2013;368:1509–1518.
94. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. *Sci Transl Med* 2013;5:177ra38.
95. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. *Sci Transl Med* 2014;6:224ra25.
96. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. *N Engl J Med* 2014;371:1507–1517.
97. Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. *Cancer Discov* 2016;6:664–679.
98. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. *Int J Cancer* 2010;127:759–767.
99. Joshi NS, Akama-Garren EH, Lu Y, Lee DY, Chang GP, Li A, et al. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. *Immunity* 2015;43:579–590.
100. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. *J Exp Med* 2009;206:1717–1725.
101. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. *J Exp Med* 2013;206:1695–1710.
102. Spranger S, Spaepen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and TIGIT in the melanoma tumor microenvironment is driven by CD8(+) T cells. *Sci Transl Med* 2013; 5:200ra116.
103. Munn DH, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. *Curr Opin Immunol* 2016;39:1–6.
104. Ugel S, De Sanctis F, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. *J Clin Invest* 2015;125:3365–3376.
105. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. *J Clin Invest* 2015;125:3356–3364.
106. De Sanctis F, Bronte V, Ugel S. Tumor-induced myeloid-derived suppressor cells *Microbiol Spectr* 2016;4:1–22.

107. Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. *Cancer Cell* 2014;26:638–652.
108. Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, et al. Critical role for CD103⁺/CD141⁺ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. *Cancer Cell* 2016;0:1–13.
109. Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. *J Clin Invest* 2011;121:4746–4757.
110. Bos PD, Plitas G, Rudra D, Lee SY, Rudensky AY. Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. *J Exp Med* 2013;210:2435–2466.
111. Ali K, Soond DR, Piñeiro R, Hagemann T, Pearce W, Lim EL, et al. Inactivation of PI(3)K p110 δ breaks regulatory T-cell-mediated immune tolerance to cancer. *Nature* 2014;510:407–411.
112. Bauer CA, Kim EY, Marangoni F, Carrizosa E, Claudio NM, Mempel TR. Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction. *J Clin Invest* 2009;119:311–327.
113. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. *Nat Immunol* 2008;9:503–510.
114. Fauriat C, Long EO, Ljunggren H-G, Bryceson. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. *Blood* 2010;115:2167–2176.
115. Reefman E, Kay JG, Wood SM, Offenhauser C, Brown DL, Roy S, et al. Cytokine secretion is distinct from secretion of cytotoxic granules in NK cells. *J Immunol* 2010;184:4852–4862.
116. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. *Immunol Rev* 2004;202:275–293.
117. Henry CJ, Ormelles DA, Mitchell LM, Brzozza-Lewis KL, Hiltbold EM. IL-12 produced by dendritic cells augments CD8⁺ T cell activation through the production of the chemokines CCL1 and CCL17. *J Immunol* 2008;181:8576–8584.
118. Jarnicki AG, Lysaght J, Todryk S, Mills KH. Suppression of antitumor immunity by IL-10 and TGF- β -producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4⁺ and CD8⁺ regulatory T cells. *J Immunol* 2006;177:7980–7989.
119. Chen W, Konkel JE. TGF- β and 'adaptive' Foxp3⁺ regulatory T cells. *J Mol Cell Biol* 2010;2:30–36.
120. Hoskin DW, Reynolds T, Blay J. Adenosine as a possible inhibitor of killer T-cell activation in the microenvironment of solid tumours. *Int J Cancer* 1994;59:854–855.
121. Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. *Cancer Res* 1997;57:2602–2605.
122. Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine mediated inhibition of T-cell activation and expansion. *Blood* 1997;90:1600–1610.
123. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashov D, Wong MK, et al. A2a adenosine receptor protects tumors from antitumor T cells. *Proc Natl Acad Sci U S A* 2006;103:13132–13137.
124. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. *J Exp Med* 2007;204:1257–1265.
125. Cekic C, Linden J. Adenosine A2a receptors intrinsically regulate CD8⁺ T cells in the tumor microenvironment. *Cancer Res* 2014;74:7239–7249.
126. Waickman AT, Alme A, Senaldi L, Zarek PE, Horton M, Powell JD. Enhancement of tumor immunotherapy by deletion of the A2a adenosine receptor. *Cancer Immunol Immunother* 2012;61:917–926.
127. Zhang B. CD73: A novel target for cancer immunotherapy. *Cancer Res* 2010;70:6407–6411.
128. Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. *Cancer Res* 2010;70:2245–2255.
129. Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. *Proc Natl Acad Sci U S A* 2010;107:1547–1552.
130. Feske S, Skolnik EY, Prakriya M. Ion channels and transporters in lymphocyte function and immunity. *Nat Rev Immunol* 2012;12:532–547.
131. Feske S, Wulff H, Skolnik EY. Ion channels in innate and adaptive immunity. *Ann Rev Immunol* 2015;33:291–353.
132. Cahalan MD, Chandy KG. The functional network of ion channels in T lymphocytes. *Immunol Rev* 2009;231:59–87.
133. Panyi G, Vamosi G, Bodnar A, Gaspar R, Damjanovich S. Looking through ion channels: recharged concepts in T-cell signaling. *Trends Immunol* 2004;25:565–569.
134. Panyi G, Bagdány M, Bodnár A, Vámosi G, Szentesi G, Jenéi A, et al. Colocalization and nonrandom distribution of Kv1.3 potassium channels and CD3 molecules in the plasma membrane of human T lymphocytes. *Proc Natl Acad Sci U S A* 2003;100:2592–2597.
135. Panyi G, Vámosi G, Bacs Z, Bagdány M, Bodnár A, Varga, et al. Kv1.3 potassium channels are localized in the immunological synapse formed between cytotoxic and target cells. *Proc Natl Acad Sci U S A* 2004;101:1285–1290.
136. Nicolaou SA, Neumeier L, Peng Y, Devor DC, Conforti L. The Ca²⁺-activated K⁺ channel KCa3.1 compartmentalizes in the immunological synapse of human T lymphocytes. *Am J Physiol Cell Physiol* 2007;292:C1431–C1439.
137. Weidinger C, Shaw PJ, Feske S. STIM1 and STIM2-mediated Ca²⁺ influx regulates antitumor immunity by CD8⁺ T cells. *EMBO Mol Med* 2013;5:1311–1321.
138. Duffy SM, Cruse G, Brightling CE, Bradding P. Adenosine closes the K⁺ channel KCa3.1 in human lung mast cells and inhibits their migration via the adenosine A2A receptor. *Eur J Immunol* 2007;37:1653–1662.
139. Chimote AA, Hajdu P, Kucher V, Boiko N, Kuras Z, Szilagyí O, et al. Selective inhibition of KCa3.1 channels mediates adenosine regulation of the motility of human T cells. *J Immunol* 2013;191:6273–6280.
140. Shi X, Bi Y, Yang W, Guo X, Jiang Y, Wan C, et al. Ca²⁺ regulates T-cell receptor activation by modulating the charge property of lipids. *Nature* 2013;493:111–115.
141. Swam M, Beck-García K, Beck-García E, Hartl FA, Morath A, Yousefi OS, et al. A cholesterol-based allosteric model of T cell receptor phosphorylation. *Immunity* 2016;44:1091–1101.
142. Zech T, Ejsing CS, Gaus K, de Wet B, Shevchenko A, Simons K, et al. Accumulation of raft lipids in T-cell plasma membrane domains engaged in TCR signalling. *EMBO J* 2009;28:466–476.
143. Molnár E, Swamy M, Holzer M, Beck-García K, Worch R, Thiele C, et al. Cholesterol and sphingomyelin drive ligand-independent T-cell antigen receptor nanoclustering. *J Biol Chem* 2012;287:42664–42674.
144. Gagnon E, Schubert DA, Gordo S, Chu HH, Wucherpfennig KW. Local changes in lipid environment of TCR microclusters regulate membrane binding by the CD3 ϵ cytoplasmic domain. *J Exp Med* 2012;209:2423–2439.
145. Yang W, Bai Y, Xiong Y, Zhang J, Chen S, Zheng, et al. Potentiating the antitumor response of CD8⁽⁺⁾ T cells by modulating cholesterol metabolism. *Nature* 2016;531:651–655.
146. Goldstein JL, Brown MS. The low-density lipoprotein pathway and its relation to atherosclerosis. *Annu Rev Biochem* 1977;46:897–930.
147. Kidani Y, Elsaesser H, Hock MB, Vergnes L, Williams KJ, Argus JP, et al. Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. *Nat Immunol* 2013;14:489–499.
148. Moller E. Contact-induced cytotoxicity by lymphoid cells containing foreign antigens. *Science* 1965;147:873–879.
149. Herlyn D, Koprowski H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. *Proc Natl Acad Sci U S A* 1982;79:4761–4765.
150. Teillaud J-L. Antibody-dependent cellular cytotoxicity (ADCC). In: eLS. Chichester, United Kingdom: John Wiley & Sons, Ltd; 2012.p.1–8.
151. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. *Nat Rev Immunol* 2010;10:317–327.
152. Bakema JE, van Egmond M. Fc receptor-dependent mechanisms of mononuclear antibody therapy of cancer. *Curr Top Microbiol Immunol* 2014;382:373–392.
153. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. *Nat Med* 2000;6:443–446.
154. Liu G, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, et al. Fc- γ receptor polymorphisms, cetuximab therapy and survival in the NCIC CTG CO.17 trial of colorectal cancer. *Clin Cancer Res* 2016;22:2435–2444.

155. Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B, Corral J, et al. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. *J Clin Oncol* 2011;29:3783–3790.
156. Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. *Blood* 2013;122:3482–3491.
157. Carmi Y, Spitzer MH, Linde IL, Burt BM, Prestwood TR, Perlman N, et al. Allogeneic IgG combined with dendritic cell stimuli induces anti-tumor T cell immunity. *Nature* 2015;521:99–104.
158. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000;100:57–70.
159. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. *Cancer Res* 1991;54:5059–5063.
160. Schmacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. *Science* 2015;348:69–74.
161. Rizvi NA, Hellman MD, Snyder A, Kvistborg P, Kakarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science* 2015;348:124–128.
162. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. *Science* 2015;350:207–211.
163. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nussbaum P, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. *Science* 2000;288:669–672.
164. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. *N Engl J Med* 2003;348:255–256.
165. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. *Science* 2003;302:415–419.
166. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. *Sci Transl Med* 2012;4:132ra53.
167. Biffi A, Bartolomea CC, Cesana D, Cartier N, Aubourg P, Ranzani M, et al. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. *Blood* 2011;117:5332–5339.
168. Vijg J. Somatic mutations and aging: a re-evaluation. *Mutat Res* 2000;447:117–135.
169. Jones IM, Thomas CB, Tucker B, Thompson CL, Pleshanov P, Vorobtsova I, et al. Impact of age and environment on somatic mutation at the hprt gene of T lymphocytes in humans. *Mutat Res* 1995;338:129–109.
170. Dempsey JL, Pfeiffer M, Morley AA. Effect of dietary restriction on *in vivo* somatic mutation in mice. *Mutat Res* 1993;291:141–145.
171. Martin GM, Ogburn CE, Colgin LM, Gown AM, Edland SD, Monnat RJ Jr. Somatic mutations are frequent and increase with age in human kidney epithelial cells. *Hum Mol Genet* 1996;5:215–221.
172. Crist SA, McCarron M, Kutlaca A, Turner DR, Morley AA. *In vivo* human somatic mutation: frequency and spectrum with age. *Mutat Res* 1992;266:189–196.
173. Dolle MET, Giese H, Hopkins CL, Martus HJ, Hausdorff JM, Vijg J. Rapid accumulation of genome rearrangements in liver but not brain of old mice. *Nat Genet* 1997;17:431–434.
174. Engle SJ, Stockelman MG, Chen J, Boivin G, Yum MN, Davies PM, et al. Adenine phosphoribosyltransferase-deficient mice develop 2,8-dihydroxyadenine nephrolithiasis. *Proc Natl Acad Sci U S A* 1996;93:5307–5312.
175. Liang L, Deng L, Shao C, Stambrook PJ, Tischfield JA. *In vivo* loss of heterozygosity in T-cells of B6C3F1 Aprt (+/-) mice. *Environ Mol Mutagen* 2000;35:150–157.
176. Cervantes RB, Stringer JR, Shao C, Tischfield JA, Stambrook PJ. Embryonic stem cells and somatic cells differ in mutation frequency and type. *Proc Natl Acad Sci U S A* 2002;99:3586–3590.
177. Gupta PK, Sahota A, Boyadjiev SA, Bye S, Shao C, O'Neill JP, et al. High frequency *in vivo* loss of heterozygosity is primarily a consequence of mitotic recombination. *Cancer Res* 1997;57:1188–1193.
178. Matta JL, Villa JL, Ramos JM, Sanchez J, Chompré G, Ruiz A, et al. DNA repair and nonmelanoma skin cancer in Puerto Rican populations. *J Am Acad Dermatol* 2003;49:433–439.
179. Ramos JM, Ruiz A, Colen R, Lopez ID, Grossman L, Matta JL. DNA repair and breast carcinoma susceptibility in women. *Cancer* 2004;100:1352–1357.
180. Busuttill RA, Rubio M, Dolle MET, Campisi J, Vijg J. Oxygen accelerates the accumulation of mutations during the senescence and immortalization of murine cells in culture. *Aging Cell* 2003;2:287–294.
181. Estrada JC, Albo C, Benguria A, Dopazo A, López-Romero P, Carrera-Quintanar L, et al. Culture of human mesenchymal stem cells at low oxygen tension improves growth and genetic stability by activating glycolysis. *Cell Death Differ* 2012;19:743–755.
182. Bertrand A, Kostine M, Barnette T, Truchetet M-E, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. *BMC Med* 2015;13:211.
183. Swaika A, Hammond WA, Joseph RW. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. *Mol Immunol* 2015;67:4–17.
184. Eggemont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. *Lancet Oncol* 2015;16:522–530.
185. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. *J Clin Oncol* 2012;30:2691–2697.
186. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood* 2015;124:188–195.
187. Bonifant CL, Jackson HJ, Brentjens RJ, Curran K. Toxicity and management in CAR T- cell therapy. *Mol Ther Oncol* 2016;3:16011.
188. van der Stegen SJ, Davies DM, Wilkie S, Foster J, Sosabowski JK, Burnet J, et al. Preclinical *in vivo* modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity? *J Immunol* 2013;191:2437–2445.
189. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. *Cancer J* 2014;20:119–122.
190. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, Pauwels EK, Jonas U, Zwartendijk J, et al. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. *Int J Cancer* 1986;38:489–494.
191. Lamers CHJ, Klaver Y, Gratama JW, Sleijfe S, Debets R. Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells- a completed study overview. *Biochem Soc Trans* 2016;44:951–959.
192. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. *Mol Ther* 2010;18:843–851.
193. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. *Blood* 2016;122:863–871.
194. Ruella M, Barrett DM, Denderian SS, Shestova O, Hofmann TJ, Perazelli J, et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. *J Clin Invest* 2016;126:3814–3826.
195. Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 Immunotherapy. *Cancer Discov* 2015; 5:1282–1295.
196. Al-Hussaini M, Rettig MP, Ritchey JK, Karpova D, Uy GL, Eissenberg LG, et al. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. *Blood* 2016;127:122–131.
197. Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. *Blood* 2005;106:4086–4092.
198. Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O, et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells *in vivo*. *Leukemia* 2014;28:1596–1605.
199. Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. *Blood* 2014;123:2343–2354.
200. Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira AC, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using

Stambrook et al.

- chimeric antigen receptors engineered to provide complementary signaling. *J Clin Immunol* 2012;32:1059–1070.
201. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. *Nat Biotechnol* 2013;31:71–75.
 202. Hedge M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, et al. Tandem CART cells targeting HER2 and IL13R α 2 mitigate tumor antigen escape. *J Clin Invest* 2016;126:3036–3052.
 203. Morsut L, Roybal KT, Xiong X, Gordley RM, Coyle SM, Thomson M, Lim WA. Engineering customized cell sensing and response behaviors using synthetic receptors. *Cell* 2016;164:780–791.
 204. Roybal KT, Rupp LJ, Morsut L, Whitney JW, McNally KA, Park JS, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. *Cell* 2016;164:770–779.
 205. Zah E, Lin M-Y, Silva-Benedict A, Jensen MC, Chen YY. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. *Cancer Immunol Res* 2016;4:498–508.
 206. Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. *Immunol Cell Biol* 2015;93:290–296.
 207. Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel immunotherapies in lymphoid malignancies. *Nat Rev Clin Oncol* 2016;13:25–40.
 208. Chmielewski M, Abken H. TRUCKS: the fourth generation of CARs. *Expert Opin Biol Ther* 2015;15:1145–1154.
 209. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. *Cytokine Growth Factor Rev* 2002;13:155–158.
 210. Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. *Blood* 2012;119:4133–4141.
 211. Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. *Cancer Res* 2011;71:5697–5706.
 212. Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. *Clin Cancer Res* 2015;21:2278–2288.
 213. Koneru M, O’Cearbhaill R, Pendharkar S, Spriggs DR, Brentjens RJ. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. *J Transl Med* 2015;13:102.
 214. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein- α . *Science* 2010;330:827–830.
 215. Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. *Cancer Immunol Res* 2014;3:815–826.
 216. Zhang Y, Ertl HCJ. Depletion of FAP $^{+}$ cells reduces immunosuppressive cells and improves metabolism and functions of CD8 $^{+}$ T cells within tumors. *Oncotarget* 2016;7:23282–23299.
 217. Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S, et al. Multiplex genome-edited T-cell manufacturing platform for "off-the-shelf" adoptive T-cell immunotherapies. *Cancer Res* 2015;75:3853–3864.
 218. Qasim W, Amrolia PJ, Samarasinghe S, Ghorashian S, Zhan H, Stafford S, et al. First Clinical application of talen engineered universal CAR19 T cells in B-ALL. *Blood* 2015;126:2046.
 219. Keller H. *The story of my life* (reissue edition 1991). New York, NY: Bantam Classics; 1903.

Molecular Cancer Research

Cancer Immunotherapy: Whence and Whither

Peter J. Stambrook, John Maher and Farzin Farzaneh

Mol Cancer Res 2017;15:635-650. Published OnlineFirst March 29, 2017.

Updated version Access the most recent version of this article at:
doi:[10.1158/1541-7786.MCR-16-0427](https://doi.org/10.1158/1541-7786.MCR-16-0427)

Cited articles This article cites 215 articles, 86 of which you can access for free at:
<http://mcr.aacrjournals.org/content/15/6/635.full#ref-list-1>

Citing articles This article has been cited by 1 HighWire-hosted articles. Access the articles at:
<http://mcr.aacrjournals.org/content/15/6/635.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://mcr.aacrjournals.org/content/15/6/635>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.